Serina Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Serina Therapeutics, Inc. (SER) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.48 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 917.00K shares, a 1552.25% increase year-over-year.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 563.00K shares, a 492.63% increase year-over-year.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 99.50K shares, a 65.83% increase year-over-year.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 250.00K shares, a 85.41% decline from fiscal 2024.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.71M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 917.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 1.48M shares 10-Q · filed 2026-08-13 | 1.58M shares derived: sum of 3 quarters · filed 2026-08-13 | 1.58M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 563.00K shares 10-Q · filed 2026-05-14 | 662.50K shares derived: sum of 2 quarters · filed 2026-05-14 | 662.50K shares derived: sum of 3 quarters · filed 2026-05-14 | 718.00K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 99.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 99.50K shares derived: sum of 2 quarters · filed 2026-03-25 | 155.00K shares derived: sum of 3 quarters · filed 2026-03-25 | 250.00K shares 10-K · filed 2026-03-25 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 55.50K shares derived: sum of 2 quarters · filed 2025-11-13 | 150.50K shares 10-Q · filed 2025-11-13 | 210.50K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 55.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 150.50K shares 10-Q · filed 2025-08-11 | 210.50K shares derived: sum of 3 quarters · filed 2025-08-11 | |
| 2025-03-31 | 95.00K shares 10-Q · filed 2025-05-08 | 155.00K shares derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2024-12-31 | 60.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | 1.71M shares 10-K · filed 2025-03-24 | ||
| 2024-09-30 | 1.65M shares 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |